National Institute on Drug Abuse - Intramural Research Program
Featured Paper of the Month – March 2025
Published in Human Brain Mapping by Justine Hill and Amy Janes, et al. of the NIDA IRP Cognitive and Pharmacological Neuroimaging Unit.
In this study, we show that methylphenidate – a drug used to treat ADHD by increasing dopamine and norepinephrine – boosts the amount of time that the brain is engaged in both internal and external attention networks.
Featured Paper of the Month – March 2025
Published in Human Brain Mapping by Justine Hill and Amy Janes, et al. of the NIDA IRP Cognitive and Pharmacological Neuroimaging Unit.
In this study, we show that methylphenidate – a drug used to treat ADHD by increasing dopamine and norepinephrine – boosts the amount of time that the brain is engaged in both internal and external attention networks.
Featured Paper of the Month – March 2025
Published in Human Brain Mapping by Justine Hill and Amy Janes, et al. of the NIDA IRP Cognitive and Pharmacological Neuroimaging Unit.
In this study, we show that methylphenidate – a drug used to treat ADHD by increasing dopamine and norepinephrine – boosts the amount of time that the brain is engaged in both internal and external attention networks.
Featured Paper of the Month – February 2025
Published in Molecular Psychiatry by Rani Richardson, Leandro Vendruscolo, and Lorenzo Leggio of the NIDA IRP.
We previously found that systemic and central administration of GHSR antagonists reduced binge-like alcohol drinking, whereas a ghrelin vaccine did not. Thus, we hypothesized that central GHSR drives binge-like alcohol drinking independently of peripheral ghrelin.
Hot Off the Press – January, 2025 Published in Nature Communications by Miriam Bocarsly, Mike Michaelides and Veronica Alvarez, et al. of the NIDA IRP. Summary Alcohol use disorder (AUD) is frequently comorbid with anxiety disorders, yet whether alcohol abuse precedes or follows the expression of anxiety remains unclear. Rodents offer control over the first drink,… [Read More]
Featured Paper of the Month – January 2025
Published in Nature Communications by Zhewei Zhang, Yuji Takahashi and Geoffrey Schoenbaum et al. of the NIDA IRP Behavioral Neurophysiology Neuroscience Section.
We studied rats with hippocampus damage as they played a smell-based game. The game involved four contexts with different reward structures changing over time.
A fast and responsive voltage indicator with enhanced sensitivity for unitary synaptic events Neuron.
The paper introduces ASAP5, a genetically encoded voltage indicator (GEVI) optimized for detecting electrical activity in neurons with improved speed, sensitivity, and signal resolution. The study highlights ASAP5’s in vitro and in vivo utility across species (flies, fish, mice, and human neurons). It bridges the gap between low-throughput electrophysiology and non-invasive imaging, making it a valuable resource for investigating synaptic dysfunction in neurodevelopmental and neurodegenerative diseases.
Featured Paper of the Month – December 2024
Published in Nature Communications Biology by András H Lékó, Adriana Gregory-Flores and Lorenzo Leggio et al. of the NIDA IRP Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section.
In this study. we investigated whether the deletion of the GHSR gene (GHSR-KO) in rats can prevent or attenuate weight gain caused by a high-fat diet.
Lorenzo Leggio, M.D., Ph.D. is a 2023 recipient of the Arthur S. Flemming Award for his exceptional service as a Federal Employee. Dr. Leggio received his award in a ceremony on November 14, 2024. The Flemming Awards are managed by the George Washington University’s Trachtenberg School of Public Policy and recipients include many notable figures… [Read More]
DART.2: bidirectional synaptic pharmacology with thousandfold cellular specificity Nat Methods.
Understanding how specific brain cells drive behavior requires targeted, cell- and circuit-specific neuropharmacology. DART.2 (Drugs Acutely Restricted by Tethering, version 2) offers improved cellular precision for targeting drugs compared to the original DART.1 technology, enabling unprecedented brain-wide drug distribution and bidirectional modulation of neurotransmitter pathways to examine behavior.
